{"disease":{"id":"chronic-iron-overload","name":"Chronic Iron Overload","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"exjade","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Exjade","company_name":"DisperSol Technologies, LLC","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH), Lysine-specific demethylase 5A","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"deferoxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Desferal","generic_name":"DEFEROXAMINE","company_name":"Mitem Pharma","drug_phase":"marketed","molecular_target":"Deoxyhypusine hydroxylase","drug_class":"Iron Chelator","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"deferasirox","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Exjade","generic_name":"DEFERASIROX","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Flavin reductase (NADPH)","drug_class":"Iron Chelator [EPC]","quality_score":10,"revenue":null,"mechanism":"Exjade works by binding to iron in the body and removing it through the urine."},{"drug_id":"desferrioxamine","indication_name":"Chronic Iron Overload","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"desferrioxamine","company_name":"Brigham and Women's Hospital","drug_phase":"phase_3","molecular_target":"Deoxyhypusine hydroxylase, Hypoxia-inducible factor 1-alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05440487","title":"Study to Assess Iron Chelation Therapy in Patients With Chronic Iron Overload","phase":"","overall_status":"COMPLETED","enrollment_count":489,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT01825512","title":"Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":435,"lead_sponsor_name":"Consorzio per Valutazioni Biologiche e Farmacologiche","has_results":true},{"nct_id":"NCT06215287","title":"Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational Materials","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02125877","title":"Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":173,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02720536","title":"Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":5},"guidelines":[],"source":"Drug Landscape verified database"}